Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

Andrei R. Shustov, MD, Amitkumar Mehta, MD, Lubomir Sokol, MD PhD, Luis A. Carvajal, PhD, Vincent Guerlavais, PhD, Manoj Samant, PhD, Narayana Narasimhan, PhD, David Sutton, BSc, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Ronald Korn, MD PhD

Blood (2018) 132 (Supplement 1): 5348.

https://doi.org/10.1182/blood-2018-99-119489

Published: 2018

Journal Articles

Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies

Rasim Gucalp, MD, Karl Insogna, MD, Mimi Hu, MD, Ilya Glezerman, MD, Sophie Leboulleux, MD, Waldemar Misiorowski, MD, Bennett Yu, MD, Paul Zorsky, MD, Diego Tosi, MD, Alberto Bessudo, MD, Arnaud Jaccard, MD, Giuseppe Tonini, MD, Wendy Ying, PhD, Ada H. Braun, MD, PhD, Rajul K. Jain, MD

Blood (2013) 122 (21): 2536.

https://doi.org/10.1182/blood.V122.21.2536.2536

Published: 2013

Journal Articles

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Noopur Raje, Robert Vescio, MD, Charles W. Montgomery, MD, Joseph T Hadala, MS, Ghulam Warsi, PhD, Solveig G. Ericson, MD, PhD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4077.

https://doi.org/10.1182/blood.V120.21.4077.4077

Published: 2012

Journal Articles

Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study

Mimi I Hu, MD, Rasim Gucalp, Karl Insogna, Ilya Glezerman, Sophie Leboulleux, Waldemar Misiorowski, Bennett Yu, Wendy Ying, Howard S. Yeh, MD

Blood (2011) 118 (21): 2483.

https://doi.org/10.1182/blood.V118.21.2483.2483

Published: 2011

Journal Articles

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Noopur Raje, MD, Robert Vescio, MD, Charles W. Montgomery, MD, Ramakrishnan Parameswaran, MD, Diep Tran, MS, Ghulam Warsi, PhD, Eliza Argonza-Aviles, RN, MSHS, Solveig G. Ericson, MD- PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 5122.

https://doi.org/10.1182/blood.V118.21.5122.5122

Published: 2011

Journal Articles

Retrospective Database Analysis of the Effect of Zoledronic Acid (ZOL) On Skeletal-Related Events (SREs) in Patients (Patients) with Multiple Myeloma (MM).

Henry J Henk, PhD, Satyin Kaura, Jose Ricardo Perez, Laura Becker

Blood (2009) 114 (22): 3881.

https://doi.org/10.1182/blood.V114.22.3881.3881

Published: 2009

Journal Articles

Osteoclasts Are Involved in the Maintenance of Dormant Leukemic Cells.

Asumi Yokota, MMSc, Shinya Kimura, MD, PhD, Ruriko Tanaka, MMSc, Miki Takeuchi, MD, Hisayuki Yao, MD, Kazuki Sakai, MD, Rina Nagao, Eishi Ashihara, MD, PhD, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 4245.

https://doi.org/10.1182/blood.V114.22.4245.4245

Published: 2009

Journal Articles

Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.

Evangelos Terpos, Richard Cook, Robert Coleman, Allan Lipton, James Berenson

Blood (2007) 110 (11): 1482.

https://doi.org/10.1182/blood.V110.11.1482.1482

Published: 2007

Journal Articles

Novel Combination of Gallium Nitrate, Rituximab and Dexamethasone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Transformed Follicular Lymphoma.

Scott E. Smith, MD, PhD, Patrick J. Stiff, MD, Tulio Rodriguez, MD, Amir Toor, MD, Jared Klein, MD

Blood (2005) 106 (11): 4755.

https://doi.org/10.1182/blood.V106.11.4755.4755

Published: 2005

Journal Articles

Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy.

Allan Lipton, Robert E. Coleman, Pierre Major, Janet E. Brown, Ker-Ai Lee, Matthew Smith, Fred Saad, YinMiao Chen, Yong Jiang, Hei, Richard Cook

Blood (2005) 106 (11): 3456.

https://doi.org/10.1182/blood.V106.11.3456.3456

Published: 2005

Journal Articles

Natural History of Skeletal-Related Events in Patients with Multiple Myeloma: Exploratory Analysis Based on Prior History of Skeletal Complications.

Mohamad A. Hussein, Mary Kaminski, Lee Rosen, David Gordon, Ming Zheng

Blood (2004) 104 (11): 4928.

https://doi.org/10.1182/blood.V104.11.4928.4928

Published: 2004

Journal Articles

Oral Cavity Avascular Bone Necrosis - a Newly Recognized Complication of Intravenous (IV) Bisphosphonate Therapy in Cancer Patients.

Michael W. Schuster, M.D., Joanne M. Dymek, RNP

Blood (2004) 104 (11): 4905.

https://doi.org/10.1182/blood.V104.11.4905.4905

Published: 2004

Journal Articles

Zoledronic Acid (ZA)- Associated Nephrotoxicity: An Analysis of Adverse Drug Reaction (ADR) Reports by the Research on Adverse Drug Events and Reports (RADAR) Project.

June M. McKoy, MD, JD, Eniola Obadina, BS, Paul R. Yarnold, PhD, Victoria Kut, MD, Dennis W. Raisch, PhD, Charles L. Bennett, MD, PhD

Blood (2004) 104 (11): 3139.

https://doi.org/10.1182/blood.V104.11.3139.3139

Published: 2004

NARROW

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Retrospective Database Analysis of the Effect of Zoledronic Acid (ZOL) On Skeletal-Related Events (SREs) in Patients (Patients) with Multiple Myeloma (MM).

Osteoclasts Are Involved in the Maintenance of Dormant Leukemic Cells.

Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.

Novel Combination of Gallium Nitrate, Rituximab and Dexamethasone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Transformed Follicular Lymphoma.

Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy.

Natural History of Skeletal-Related Events in Patients with Multiple Myeloma: Exploratory Analysis Based on Prior History of Skeletal Complications.

Oral Cavity Avascular Bone Necrosis - a Newly Recognized Complication of Intravenous (IV) Bisphosphonate Therapy in Cancer Patients.

Zoledronic Acid (ZA)- Associated Nephrotoxicity: An Analysis of Adverse Drug Reaction (ADR) Reports by the Research on Adverse Drug Events and Reports (RADAR) Project.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only